Medigen, Inc. is a preclinical biomedical company that specializes in the development of safe and effective vaccines for emerging infectious diseases and cancer.
We develop our vaccines by using novel vaccine technologies such as virus-like particles (VLPs) and genetic vectors. Medigen also develops new ways of vaccine delivery for effective and safe immunization.
Our experimental vaccines include prostate cancer vaccine, as well as vaccines against pandemic influenza, chikungunya fever and other emerging, re-emerging, and biodefense-relevant infectious diseases.
In addition to vaccine development, we perform contract research and assist our customers in their research and development needs.
Medigen, Inc. conducts scientific research and vaccine development in the areas of infectious diseases, cancer, and gene therapy. Medigen scientists are the leading experts in these areas.
We developed unique platform technologies for vaccination against cancer and infectious diseases. These platform technologies are applicable to the vaccine development against many diseases that affect millions of people in the U.S. and worldwide.
Using our platform technologies, we developed candidate vaccines for prostate cancer, pandemic influenza, chikungunya fever, VEE virus, and yellow fever. These vaccines are being tested in animals.
We provide our customers with expert contract research services, including experiment design, intellectual property development, and publishing and presenting data to the scientific community and government agencies. Our expertise includes production of viruses and virus-like particles, characterization of VLPs and purification of VLPs. Contact us for further details or request a quote at
Welcome to Medigen new web site!
In recent months, we had several important developments. To name just a few:
Copyright 2013 Medigen, Inc. All rights reserved.